This finding was supported by both blinded independent central review (BICR)-assessed and investigator-assessed progression-free survival [11, 14]. In summary, the use of PARP inhibitors such as olaparib and talazoparib in the OlympiAD and EMBRACA trials demonstrated improved progression-free survival and response rates compared to standard therapy for HER2-negative metastatic BC with gBRCA mutations, particularly in patients with no prior chemotherapy. The gene discussed is PARP1; the disease is breast cancer.